Physician profile
Allissa M Walker
NPI 1194593491
$1,531.11
in general payments reported to CMS, 2019-2025
17 companies · $34.86 in 2025
The $34.86 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,496 · 2025: $34.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $328.32 | 2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $287.53 | 2024 | Entyvio |
| Abbvie INC. | $146.01 | 2024-2025 | |
| Lilly USA, LLC | $137.54 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $130.89 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.62 | 2024 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $85.77 | 2024 | |
| Fresenius Kabi USA, LLC | $56.55 | 2024 | Idacio |
| Ardelyx, INC. | $37.96 | 2024 | Ibsrela |
| Novo Nordisk INC | $34.08 | 2024 | |
| Madrigal Pharmaceuticals | $32.49 | 2024 | Resmetirom |
| Regeneron Healthcare Solutions, INC. | $29.96 | 2024 | Dupixent |
| Vivus LLC | $29.74 | 2024 | Pancreaze |
| Genzyme Corporation | $25.05 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $25.03 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $18.67 | 2025 | |
| Ironwood Pharmaceuticals, INC | $16.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allissa Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.